Why is Iovance Biotherapeutics stock sliding today?

Shares of Iovance Biotherapeutics fell 8.9% in pre-open trading today, reversing a sharp overnight gain after investors appeared to sell into the details of the company’s much-anticipated Phase 2 lung cancer data webcast. The stock had risen roughly 12% after hours on October 28 after the company announced positive results from the registrational cohorts of its Phase 2 lung cancer trial, with full details scheduled for an October 29 webcast. The company described the results for its one-time lifileucel therapy as positive, drawn from IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous metastatic non-small cell lung cancer, with the discussion also set to cover precision-based medicine opportunities for its tumor-infiltrating lymphocyte therapy platform.

The pre-market pullback reflects a combination of profit-taking and tempered expectations heading into the webcast. One analyst article cautioned that IOVA may already reflect much of the benefit from recent ESMO-related data, raising valuation and profit-taking risks after the stock’s substantial rally. At a market value of roughly $7 billion, Iovance trades near 17 times the midpoint of its 2026 revenue guidance — a high multiple for a company that is not yet profitable, though common for biotechs with growing approved products and pipeline expansion. Notably, the October 28 announcement contained no specific efficacy figures or patient numbers ahead of the webcast, leaving investors to reassess whether the actual data would meet the elevated bar set by the overnight enthusiasm.

The Federal Reserve voted on October 28 to keep benchmark interest rates on hold, maintaining the overnight funds rate in a range between 3.75% and 4%, opting for a patient approach in its fight against inflation. Two of the 12 FOMC voters dissented, both wanting the committee to raise rates by a quarter percentage point, while the post-meeting statement noted that inflation "remains elevated." Longer-term Treasury yields rose in response, and elevated long-term yields can put pressure on stock valuations, especially for companies whose expected profits lie many years in the future. The broader NASDAQ is also under pressure today, compounding the headwind for high-multiple biotech names.

The combination of a "buy the rumor, sell the news" dynamic, stretched valuation concerns, and a mildly hawkish macro backdrop has driven IOVA’s pre-market reversal. Investors will be watching the webcast closely for whether the response rate holds above the interim 25.6% in the full registrational cohorts, how durable the responses are, and whether the safety profile supports use outside major academic centers — factors that will ultimately determine whether today’s pullback proves to be a short-lived reset or a more sustained correction ahead of Q3 earnings on November 5.